Clinical Trial 21887

A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes

Disease Site: Other

PI: Padron, Eric

Clinical Trial 21986

A Phase 2, Multicenter, Randomized, Open-Label Study of DS-7300a, a B7-H3 Antibody Drug Conjugate (ADC), in Subjects with Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Disease Site: Lung

PI: Chiappori, Alberto

Clinical Trial 21997

Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

Disease Site: Other Skin

PI: Eroglu, Zeynep

Clinical Trial 22002

A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS

Disease Site: Any Site, Liver, Lung, Other Digestive Organ, Pancreas, Small Intestine, Stomach

PI: Kim, Dae Won

Clinical Trial 22003

A Phase II Randomized Study of Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) in Metastatic Prostate Cancer with PSA Progression while on NHA and LHRH Analog

Disease Site: Prostate

PI: Zhang, Jingsong

Clinical Trial 20178

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Disease Site: Lung, Non small cell lung cancer

PI: Saltos, Andreas

Clinical Trial 20305

Phase 1/1b Trial of Donor gamma delta T-cell Infusion for Treatment of Patients with Acute Myeloid Leukemia at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation

Disease Site: Leukemia, other, Myeloid and Monocytic Leukemia

PI: Bejanyan, Nelli

Clinical Trial 20339

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma

Disease Site: Bones and Joints, Rhabdomyosarcoma

PI: Metts, Jonathan

Clinical Trial 20386

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC

Disease Site: Lung

PI: Gray, Jhanelle

Clinical Trial 22071

Melanoma Margins Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma

Disease Site: Other

PI: Zager, Jonathan

Clinical Trial 22095

Disease Site: Myeloid and Monocytic Leukemia

PI: Kuykendall, Andrew

Clinical Trial 22096

A Phase 1 Open-Label, Dose-Escalation, Safety, and Tolerability Study of JSP191 as a Second-line Therapy in Subjects with Lower-Risk Myelodysplastic Syndrome (LR-MDS)

Disease Site: Other Hematopoietic

PI: Lancet, Jeffrey